<DOC>
	<DOCNO>NCT01187381</DOCNO>
	<brief_summary>This single arm observational study assess duration safety treatment Herceptin ( trastuzumab ) routine clinical practice patient early metastatic HER2-positive breast cancer . Data collect female patient treat Herceptin accord Summary Product Characteristics local protocol . Duration observation patient therapy initiation permanent discontinuation cause .</brief_summary>
	<brief_title>An Observational Study Mean Duration Herceptin ( Trastuzumab ) Treatment Patients With Early Metastatic HER2-positive Breast Cancer ( HERODOT )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient , &gt; /= 18 year age HER2positive breast cancer Treated Herceptin accordance Summary Product Characteristics local protocol Written inform consent data collection Any contraindication Herceptin Clinically relevant cardiovascular disorder disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>